0 CHECKOUT

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update

  • ID: 3742627
  • June 2016
  • Region: Global
  • 462 Pages
  • La Merie Publishing
1 of 4

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Dong-A ST
  • Immunomedics
  • Mylan Pharmaceuticals
  • Shanghai Henlius Biotech
  • MORE

This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target.

The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 - 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R).

Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Dong-A ST
  • Immunomedics
  • Mylan Pharmaceuticals
  • Shanghai Henlius Biotech
  • MORE

A) 2015 Sales of Therapeutic Antibodies
- Overview: 2015 Biologics Sales per Class of Products
- Overview: 2015 Therapeutic Antibody Sales per Class of Products
- Blockbuster Therapeutic Antibodies in 2015
- Anti-TNF Antibody Sales in 2015
- Cancer Antibody Sales in 2015
- Other Anti-Inflammatory Antibody Sales in 2015
- Ophthalmic Antibody Sales in 2015
- Cardiometabolic & Anti-Infective Antibody Sales in 2015

B) Biosimilar and Biosuperior Anti-TNF Antibodies - 2016 Update

1. Originator Anti-TNF Antibodies
- Approved and Marketed Indications of anti-TNF Antibodies in Regulated Markets
- 2015 Sales of Anti-TNF Antibodies
- Sales of Anti-TNF Antibodies in Q1/2016
- Humira Pipeline of Recently Approved Indications & Upside Developments
- Remicade Pipeline of Recent Approvals & Upside Indications
- Enbrel Pipeline of Upside Indications
- Simponi Pipeline of Recent Approvals & Upside Indications
- Cimzia Pipeline of Recent Approvals & Upside Indications
- Defense Strategies against Biosimilar Anti-TNF Antibodies

2. Biosuperior Anti-TNF Antibodies
- Non-Antibody Anti-TNF Biosuperiors
- Anti-TNF Biosuperior Antibodies

3. Biosimimilar Anti-TNF Antibodies
Humira Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets
Enbrel Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets
Remicade Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Market
Simponi & Cimzia Biosimilar Antibodies

C) Biosimilar and Biosuperior Anti-VEGF/-R Antibodies - 2016 Update

1) Marketed Anti-VEGF/R Products in Oncology
- Avastin, Zaltrap & Cyramza Sales 2008 - 2015
- Avastin Sales and Indication Portfolio
- Zaltrap Sales and Indication Portfolio
- Cyramza Sales and Indication Portfolio

2) Anti-VEGF Biosuperiors of Avastin and Zaltrap
- Anti-VEGF Biosuperior Pipeline in Oncology
- Bispecific Anti-VEGF Pipeline in Oncology

3) Anti-VEGF-R Biosuperiors of Cyramza
- Anti-VEGF-R Biosuperior Pipeline in Oncology
- Bispecific Anti-VEGF-R Pipeline in Oncology

4) Avastin & Cyramza Biosimilar Pipeline in Oncology

5) Marketed Anti-VEGF Products in Ophthalmology
- Lucentis & Eylea Sales 2008 - 2015
- Lucentis Sales & Indication Portfolio
- Eylea Sales & Indication Portfolio

6) Anti-VEGF Biosuperiors of Lucentis and Eylea
- Biosuperior Anti-VEGF in Ophthalmology
- Biosuperior Bispecific Anti-VEGF and Anti-VEGF Combinations in Ophthalmology

7) Other Anti-VEGF Molecules in Ophthalmology

8) Lucentis Biosimilars in Ophthalmology

9) Eylea Biosimilars in Ophthalmology

10) Off-Label Use of Anti-VEGF in Ophthalmology

D) Biosimilar and Biosuperior Anti-Her2 Antibodies - 2016 Update

1. 2015 Anti-Her2 Antibody Sales

2. Originator Anti-Her2 Antibodies
- Herceptin Approved Indications & Pipeline
- Perjeta Approved Indications & Pipeline
- Kadcyla Approved Indications & Pipeline

3. Biosuperior Anti-Her2 Antibodies
- 3rd Generation Anti-Her2 Antibodies
- Bispecific Anti-Her2 Antibodies
- Anti-Her2 Antibody-Drug Conjugates, Immunotoxins, Immunocytokines & Radiopharmaceuticals

4. Biosimilar Anti-Her2 Antibodies
- Herceptin Biosimilar Antibodies
- Developments in Regulated Markets
- Development in Less Regulated Markets

5. Perjeta Biosimilar Antibodies

E) Biosimilar and Biosuperior Anti-CD20 Antibodies - 2016 Update

1. 2015 Sales of Anti-CD20 Antibodies

2. Originator Anti-CD20 Antibodies
- Rituxan / MabThera Approved Indications & Pipeline
- Gazyva Approved Indications & Pipeline
- Arzerra Approved Indications and R&D Pipeline
- Zevalin Approved Indications

3. Biosuperior Anti-CD20 Antibodies
- 3rd Generation Anti-CD20 Antibodies
- Bispecific Anti-CD20 Antibodies
- Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines

4. Biosimilar Anti-CD20 Antibodies
Rituxan/MabThera Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets

5. Arzerra Biosimilar Antibodies

F) Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

1. Sales of Anti-EGF-R Antibodies

2. Originator Anti-EGF-R Antibodies
- Erbitux Approved Indications & Pipeline
- Vectibix Approved Indications & Pipeline
- Nimotuzumab Approved Indications & Pipeline
- Portrazza Approved Indications & Pipeline

3. Biosuperior Anti-EGF-R Antibodies
- 3rd Generation Anti-EGF-R Antibodies
- Bispecific Anti-EGF-R Antibodies
- Anti-EGF-R Antibody Drug Conjugates

4. Biosimilar Anti-EGF-R Antibodies
Erbitux Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets

G) Next Wave of Biosimilar Antibodies - 2016 Update
- Abatacept Biosimilar Antibodies
- Aletuzumab Biosimilar Antibodies
- Denosumab Biosimilar Antibodies
- Eculizumab Biosimilar Antibodies
- Omalizumab Biosimilar Antibodies
- Palivizumab Biosimilar Antibodies
- Tocilizumab Biosimilar Antibodies
- Ustekinumab Biosimilar Antibodies
- Biosimilars of Immune Checkpoint Inhibitor Antibodies

H) Corporate Biosimilar & Biosuperior Therapeutic Antibody Pipelines

Note: Product cover images may vary from those shown
3 of 4

- 3SBio (Shenyang Sunshine Pharmaceutical Co)
- AET Biotech
- AREVA Med
- AVEO Pharmaceuticals
- AbClon
- AbbVie
- Ablynx
- Affibody
- Affilogic
- Affimed Therapeutics
- Affitech
- Allergan
- Alopexx Oncology
- Alteogen
- Alvogen
- Ambrx
- Amega Biotech
- Amgen
- AngioChem
- Apexigen
- Aprogen
- Archemix
- Aryogen
- Ascendis Pharma
- AstraZeneca (MedImmune)
- Avaxia Biologics
- Axxo
- Baliopharm
- Baxalta
- Bayer
- biOasis Technologies
- Binex
- Bio Farma
- BioCND
- BioXpress Therapeutics
- Biocad
- Biocon
- Bioeq
- Biogen
- Bionovis
- Boehringer Ingelheim
- Bristol-Myers Squibb
- CIMAB
- Celgene
- Celltrion
- Centrose
- Ceres Oncology
- Chengdu Kanghong Biotech Co.
- Cipla
- Clearside Biomedical
- Coherus Biosciences
- Complix
- Cristalia
- Curaxys
- CytomX Therapeutics
- Daewoong Pharmaceutical Co
- Daiichi Sankyo
- Delenex Therapeutics
- Dermira
- Dong-A ST
- Dr Reddy’s Laboratories
- Eddingpharma
- Eisai
- Eli Lilly
- EnGenlC
- Epirus Biopharmaceuticals
- Esperance Pharmaceuticals
- Exicure
- Ferring Pharmaceuticals
- ForSight VISION4
- Fosun Pharma
- Fujifilm Kyowa Kirin Biologics
- Gansu Duyiwei Biological Pharmaceutical Co
- Gedeon Richter
- GenIlac
- Gene Techno Science (GTS)
- Genor Biopharma
- Glenmark Pharmaceuticals
- Gliknik
- Glycotope
- Green Cross
- Halozyme
- HanAll Pharmaceuticals
- Hanwha Chemical Biologics Business
- Harvest Moon Pharmaceuticals
- Helvetic BioPharma
- Hetero Group
- Hyprocell
- IBC Generium
- Ildong Pharmaceutical
- Immune Pharmaceuticals
- ImmuneXcite
- Immunomedics
- Innogene Kalbiotech
- Innokeys
- Innovent Biologics
- Intas Pharmaceuticals
- JHL Biotech
- Janssen (Johnson & Johnson)
- Jiangsu Simcere Pharmaceutical
- Jiangsu T-mab Biopharma
- Kissei Pharmaceutical
- Kyowa Hakko Kirin
- LG Life Sciences
- LegoChem
- Libbs Farmaceutica
- MabTech
- MabXience
- Mabion
- MacroGenics
- Meiji Seika
- Merck (MSD)
- Merck Biopharma & HealthCare Biosimilars
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Merus
- Mitsubishi Tanabe Pharma
- Mochida
- Molecular Partners
- Molecular Templates
- Momenta Pharmaceuticals
- Mundipharm
- Mycenax Biotech
- Mylan Pharmaceuticals
- Nanogen Biopharmaceutical Co
- Natco Pharma
- Neurotech
- Nichi-iko Pharmaceutical
- Nippon Kayaku
- Novartis (& Sandoz/Alcon)
- OncoMed Pharmaceuticals
- Oncobiologics
- Ophthea
- Ophthotech
- Orygen Biotecnologia
- PanOptica
- Paras Biopharmaceuticals
- Pfenex
- Pfizer (& Hospira)
- PharmAbcine
- Pharmamar
- Pharmapraxis
- Pieris Pharmaceuticals
- PlantForm
- Polpharma Group
- Probiomed
- Protalix Biotherapeutics
- Ranbaxy
- Regeneron Pharmaceuticals
- Reliance Life Sciences
- Roche
- STC Biologics
- Samsung Bioepis (JV of Samsung and Biogen)
- Sanofi
- Senju Pharmaceutical
- Shanghai Biomabs Pharmaceutical
- Shanghai Celgen BioPharmaceutical Co
- Shanghai Citi Pacific (CO) Guojian Pharmaceutical Co (CPGP)
- Shanghai Fudan-Zhangjiang BioPharmaceuticals
- Shanghai Henlius Biotech
- Shanghai Zhangjiang Biotechnology (ZJ-Bio)
- Sirnaomics
- Sorrento Biologics/Therapeutics
- Spectrum Pharmaceuticals
- Stada Arzneimittel
- Syd labs
- Symphogen
- Synthon Biopharmaceuticals
- TG Therapeutics
- TPG Biologics
- TSH Pharma
- Taisho Pharmaceutical
- Takeda Pharmaceutical Co
- Therapeutics Protein International (TPI)
- Tillots Pharma
- Torrent Pharma
- Trimer Biotech
- Triphase Accelerator
- Tyrogenex
- UCB
- Unum Therapeutics
- Vaccinex
- Valeant Pharmaceuticals
- Valor Biotherapeutics
- Wuhan YZY Biopharma
- Xbrane Biopharma
- Xencor
- YL Biologics
- Yuhan
- Zhejiang Huahai Pharmaceutical Co
- Zhejiang Medicine
- Zova Biotherapeutics
- Zydus Cadila
- Zymeworks
- Zyngenia

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

ALSO AVAILABLE

RELATED PRODUCTS from Cache

Our Clients

  • Abbott Laboratories Ltd.
  • Covance Inc.
  • Accord Healthcare
  • BioMarin Pharmaceutical Inc.
  • Biocad
  • Catalent